salsalate
Trade name: salflex
Small moleculeexperimental
Salsalate is a dimer of salicylic acid. Upon administration, it is metabolically hydrolyzed to salicylic acid. Salsalate is is a nonsteroidal anti-inflammatory agent for oral administration for treatment of rheumatoid arthritis, osteoarthritis and related rheumatoid disorders. In addition, salsalate is investigated for treatment of type 2 diabetes. — NCATS
Clinical trial activity
35 trials · 35 clinical orgs · 0 marketing orgs
Phase 1
11
Phase 2
8
Phase 3
6
Phase 4
3
Earliest trial started Mar 1, 2003 (NCT00339833)
Timeline
Indications
Approved for
Studied for
- Alzheimer Disease · Phase 1
- Anemia · Phase 2
- Atherosclerosis · Phase 2/Phase 3
- Bone Marrow Cells · Phase 2
- Cardiovascular Diseases · Phase 2/Phase 3
- Coronary Artery Disease · Phase 2/Phase 3
- Diabetes Mellitus · Phase 4
- Diabetes Mellitus, Type 1 · Phase 2/Phase 3
- Diabetes Mellitus, Type 2 · Phase 4
- Diabetic Neuropathies · Early Phase 1
- Endometriosis · Early Phase 1
- Endothelial Cells · Phase 2
- Healthy Volunteers · Phase 1
- Heart Failure, Diastolic · Phase 2
- HIV · Phase 2
- Hyperglycemia · Phase 1
- Inflammation · Phase 2/Phase 3
- Insulin Resistance · Phase 2/Phase 3
- Leukemia, Myeloid, Acute · Phase 2
- Leukemia, Myelomonocytic, Chronic · Phase 2
- Myelodysplastic Syndromes · Phase 2
- Myeloproliferative Disorders · Phase 2
- Non-alcoholic Fatty Liver Disease · Phase 4
- Obesity · Phase 2
- Osteoarthritis · Phase 4
- Overweight · Phase 2/Phase 3
- Peripheral Nervous System Diseases · Phase 2/Phase 3
- Polycystic Ovary Syndrome · Phase 2
- Postoperative Complications · Phase 1
- Prediabetic State · Phase 2
- Pre-Eclampsia · Early Phase 1
- Psychotic Disorders · Phase 4
- Schizophrenia · Phase 4
- Supranuclear Palsy, Progressive · Phase 1
- Vaping · Early Phase 1
- Vascular Stiffness · Phase 2
Mechanism of action
- Unspecified targetUnclear
Unclear
Chemistry & pharmacology
Loading structure…
SMILES
OC(=O)C1=CC=CC=C1OC(=O)C2=CC=CC=C2O- Mol. weight
- 258.2262 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Prodrug
Sources
- WikipediaSalsalate ↗
- NCATSV9MO595C9I ↗
- ChEMBLCHEMBL154111 ↗
Also known as
- 2-carboxyphenyl salicylate
- 2-carboxyphenyl salicylate
- acetylated salicylate
- arcylate
- argesic
- disalcid
- disalcid
- disalcid
- disalicylic acid
- disalicylic acid
- disalicylic acid
- disalicylic acid
- disalicylsaeure
- disalicylsaeure
- mono-gesic
- o-salicylcylsalicylsaeure
- o-salicylcylsalicylsaeure
- o-salicylsalicylic acid
- o-salicylsalicylic acid
- salflex
- salicylic acid bimolecular ester
- salicylic acid bimolecular ester
- salicylic acid salicylate
- salicyloxysalicylic acid
- salicyloxysalicylic acid
- salicyloxysalicylic acid
- salicyloylsalicylic acid
- salicyloylsalicylic acid
- salicyloylsalicylic acid
- salicyl salicylate
- salicyl salicylate
- salicylsalicylic acid
- salicylsalicylic acid
- salicylsalicylic acid
- salicylsalicylic acid
- salicylsalicylic acid
- saloxium
- salsalate
- salsalate
- salsalate
- salsalate
- salsalate
- salsalate
- salsalate
- salsalate
- salsalate
- salsalate
- salsalato
- salsalato
- salsalatum
- salsalatum
- salsitab
- sasapyrin
- sasapyrin
- sasapyrine
- sasapyrine
- sasapyrine
- sasapyrine
- sasapyrinum
- sasapyrinum
- upsher-smith brand of salicylsalicylic acid
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06489249 | Early Phase 1 (Phase 1) | Aug 15, 2024 | University of Iowa |
| NCT05169060 | Early Phase 1 (Phase 1) | Nov 1, 2022 | University of Iowa, University of Michigan |
| NCT05069740 | Early Phase 1 (Phase 1) | Jan 1, 2022 | Pennsylvania State University |
| NCT04146038 | Phase 2 | Dec 15, 2019 | National Cancer Institute (NCI), Rutgers University |
| NCT03816488 | Phase 1 | Jun 1, 2019 | McMaster University |
| NCT03229408 | Phase 2 | Jan 31, 2018 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), University of Illinois at Chicago |
| NCT03222206 | Phase 4 | Nov 8, 2017 | Korea University, Kuhnil Pharmaceutical Co., Ltd. |
| NCT03482440 | Early Phase 1 (Phase 1) | Aug 23, 2017 | Pennsylvania State University |
| NCT03277573 | Phase 1 | Jul 21, 2017 | University of California, San Francisco |
| NCT02936843 | Phase 2/Phase 3 (Phase 3) | Oct 1, 2016 | University of Michigan |
| NCT02422485 | Phase 1 | Apr 1, 2015 | University of California, San Francisco |
| NCT01977417 | Phase 2 | Nov 1, 2012 | University of Iowa |
| NCT01775865 | Phase 2 | Sep 1, 2012 | University of Iowa |
| NCT01670773 | Phase 1 | Aug 1, 2012 | Catabasis |
| NCT01514682 | N/A | Jun 1, 2012 | University of Maryland |
| NCT01506726 | Phase 2 | Mar 1, 2012 | Duke University, Johns Hopkins University, National Institute on Aging (NIA), Stanford University |
| NCT01489319 | Phase 1 | Feb 1, 2012 | Indiana University |
| NCT01480297 | Phase 2 | Nov 1, 2011 | University of Michigan |
| NCT02130804 | Phase 1 | Jul 1, 2011 | University of Southern California |
| NCT01578486 | Phase 4 | Jun 1, 2011 | National Institutes of Health (NIH), University of Massachusetts |
Showing 20 of 35 trials
Page 1 / 2
Organizations
Research & Development (35)
35 organizations
Page 1 / 2